UCB Japan launched its anti-neonatal Fc receptor (FcRn) monoclonal antibody Rystiggo (rozanolixizumab) for the treatment of generalized myasthenia gravis (gMG) in Japan on November 28. The drug is indicated for treating adult patients with gMG, but only in those who…
To read the full story
Related Article
- UCB Rolls Out gMG Drug Zilbrysq in Japan
February 19, 2024
- UCB Japan Gathers Pace in Rare Disease Space with 2 New Launches for gMG
November 28, 2023
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





